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IN VIVO IMMUNOTOXICOLOGICAL EVALUATION OF ELECTROSPUN
POLYCAPROLACTONE (EPCL) AND INVESTIGATION OF EPCL AS A DRUG
DELIVERY SYSTEM FOR IMMUNOMODULATORY COMPOUNDS
By Colleen Elizabeth McLoughlin, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Biomedical Engineering at Virginia Commonwealth University.
Virginia Commonwealth University, 2012
Major Director: Gary L. Bowlin, Ph.D.
Professor, Department of Biomedical Engineering
Co-Director: Kimber L. White, Jr., Ph.D.
Professor, Department of Pharmacology and Toxicology

Electrospun materials have potential use in many biomedical applications such as
soft tissue replacements or as scaffolds to target drug delivery to local sites.
Electrospinning is a polymer processing technique that can be used to create materials
composed of fibers with diameters ranging from the micron to the nanoscale.

We

investigated the effects of microfibrous and nanofibrous electrospun polycaprolactone
xx

xxi
(EPCL) on innate, cell-mediated, and humoral components of the immune system. Results
demonstrated that in both young (12 week) and old (6 month) mice, EPCL had no effect on
various immune parameters. With its lack of immunotoxicity, EPCL presents an excellent
polymer scaffold for use in delivering drugs to local sites. Drug delivery studies focused
on using EPCL nanofiber scaffolds with the known immunosuppressive compound
dexamethasone (DEX) incorporated within the matrix. The ability of the EPCL-DEX
scaffold to suppress cell-mediated immunity (CMI) was evaluated using the delayed-type
hypersensitivity (DTH) response to Candida albicans. Preliminary studies were conducted
following subcutaneous implantation of a single disk (6-mm or 3-mm diameter) with 3, 10,
30, or 100 % w/w DEX in EPCL in the thigh region. Based on footpad swelling, dose responsive suppression of the DTH was observed based on DEX equivalent units (DEU) at
all but the lowest dose. The animals that received the high dose (100% in 6-mm) had
decreased spleen weights, however no change in spleen weight was observed at the lower
doses. Thymus weights were only affected at the four highest doses. These preliminary
results suggest that implantation of a drug-containing electrospun scaffold may achieve
local immunosuppression without systemic toxicity. Finally, we evaluated the EPCL-DEX
scaffold in an acute inflammatory model (keyhole limpet hemocyanin) and a mouse model
of rheumatoid arthritis (collagen induced arthritis). While similar trends were observed in
the other models, the EPCL-DEX system achieved greatest success in the DTH model.
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CHAPTER 1: Introduction

Tissue engineering, nanomedicine, and nanotoxicology
Tissue engineering is an interdisciplinary field requiring participants from engineers,
biologists, immunologists, and clinicians, amongst others, which has grown widely since the late
1980s. Tissue engineering aims to create therapies that can improve, maintain, or restore tissue
function, typically through the creation of a scaffold intended to mimic native tissue [Boland et
al. 2004a]. The goal in creating a scaffold is generally to mimic both the structure and function
of the extracellular matrix (ECM). An important characteristic is size and since the ECM has
fibers on the order of nanometers this leads to the development of nanomaterials for use in tissue
engineering. Nanobiomaterials and tissue-engineered products can also be considered a part of
the larger field of nanomedicine.
The use of nanomaterials in medicine can offer many advantages but also cause concern
about adverse effects due to the potential for the same characteristics that make nanomaterials
attractive for use can lead to unique toxicity profiles. In addition to tissue engineering therapies,
nanomedicines include therapies for drug delivery and diagnostic tools [Kagan et al. 2005].
Common materials range from metals to carbon-based nanomaterials, metal-based
nanomaterials, biologicals, nanoceramics and nanocomposites, to nanopolymers [Zhao and
Castranova 2011]. The focus here is on nanofibrous polymers, and biocompatibility and toxicity
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testing of nanopolymers, with emphasis on immune responses to biomaterials and
immunotoxicity.

Nanofibrous polymers and processing techniques
Due to the limitation of conventional polymer processing techniques being unable to
achieve fiber diameters smaller than 10µm, methods of nanofiber generation have been
developed which include self-assembly, phase separation, and electrospinning. Self-assembly
allows for the creation of the smallest fiber diameters (5-8nm), however, it involves a difficult
laboratory procedure which is limited to a small number of polymers. Phase separation offers
several advantages including high control over architecture, batch-to-batch consistency, and a
simple process, however the technique is limited to few polymers and produces a low yield.
Electrospinning has been highly favored by researchers because it is easy and inexpensive, can
be used with a large variety of natural and synthetic polymers, and provides the ability to control
fiber size on the nano to micron scale, however disadvantages include that the smallest fiber
sizes tend to be larger than other methods and the use of organic solvents [Barnes et al. 2007].

Biocompatibility and toxicity testing of nanopolymers
Biocompatibility testing, including most often in vitro cytocompatibility and
hematocompatibility tests, can provide important initial insight for biomaterial testing.
According to the Williams definition of biocompatibity for tissue-engineering products “The
biocompatibility of a scaffold or matrix for a tissue-engineering product refers to the ability to
perform as substrate that will support the appropriate cellular activity, including the facilitation
of molecular and mechanical signaling systems, in order to optimize tissue regeneration, without
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eliciting any undesirable effects in those cells, or inducing any undesirable local or systemic
responses in the eventual host” [Williams 2003]. In spite of this definition, the term
“biocompatibility” pervades the literature with inconsistent use and is often applied without
knowledge of the in vivo response that may include systemic effects unable to be assessed in
vitro. Of particle interest for nanopolymers is the potential of degradation products on the
nanoscale to have adverse effects. Upon implantation of biomaterials, immune cells immediately
come in to contact with the material and therefore the immune response is of particular
importance [Ratner et al. 2004].

The immune system and response to biomaterials
The immune system protects the body from infection through physical barriers (skin),
cells, and organs. The immune system is divided into two main branches, innate immunity, and
acquired immunity. Innate immunity is the first to respond and includes skin, macrophages,
neutrophils, natural killer cells, and complement proteins. Innate immune responses are directed
against generic pathogens. Pathogens have pathogen-associated molecular patterns (PAMPs)
which are recognized by innate immune cells through pattern recognition receptors (PRRs). The
innate response is rapid. In contrast to the innate immune response, the acquired immune
response is specific to antigen, and is slow to respond following the first contact with a new
antigen. The cellular components, T-cells and B-cells can form antigen-specific memory and
upon re-exposure respond quickly to the antigen [Janeway, 2008]. Upon implantation of a
biomaterial, injury and inflammation occurs and neutrophils and monocytes infiltrate the site.
Due to protein absorption on the biomaterial surface, complement activation occurs activating
macrophages. The acute inflammatory phase is followed by a chronic inflammatory and foreign
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body reaction both mediated by macrophages [Franz et al. 2011]. Currently, researchers are
exploring ways to change the immune response to biomaterials at the surface through surface
modifications, incorporation of bioactive molecules, and through incorporation of drugs and
growth factors [Franz et al. 2011]. However, the focus of immune response testing remains
primarily in the surface phenomenon and little attention has been given to potential systemic
immunomodulatory effects of biomaterials/nanopolymers.
In several works by Smith et al. an immunotoxicological approach was used to study
several electrospun polymers, primarily blends of polydioxanone and collagen and
polydioxanone and elastin, on immune cell function responses in vitro [Smith et al. 2007, Smith
et al. 2009, Smith et al. 2010]. Results indicated that some electrospun polymers can potentially
cause immunotoxicity to innate and acquired immune responses in vitro. Recently, work has
been done to examine an electrospun polymer, polycaprolactone, (or EPCL) for potential
immunotoxicity in vivo. McLoughlin et al. studied both microfibrous and nanofibrous EPCL and
found neither configuration affected innate or acquired immune functions tested [McLoughlin et
al. 2012].
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CHAPTER 2: Research Design

Rationale and Major Hypotheses
The research goal was to investigate the immunomodulatory effects of EPCL utilizing
both micron and nano-sized fiber diameters, in vivo, in both young adult (3 months of age) and
aged (6-month-old) mice. Based on these results showing a lack of effect with either fiber size on
either age group, a preliminary study was conducted to establish doses of dexamethasone-loaded
EPCL able to deliver the drug locally to an inflamed joint in both an acute and a systemic
inflammatory model without systemic effects (including spleen and thymus weights). To this
end, we proposed the following hypothesis: in vivo exposure to dexamethasone-loaded
electrospun polycaprolactone will dose-responsively cause suppression of local joint and footpad
swelling in mouse inflammatory models with minimal systemic immunosuppression.
Specific Aims
In order to test the hypotheses four specific aims were developed. To test the hypothesis
that nanofibrous EPCL would cause greater dose-responsive immunosuppression than
microfibrous EPCL and that aged animals would be more susceptible to the immunotoxic effects
specific aim 1 was developed. Specific aim 1 was to determine the effects of electrospun
polycaprolactone materials on various innate and acquired immune responses following in vivo
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exposure of 3-month-old (young adult) B6C3F1 mice to determine effects using nano fiber
diameter electrospun materials and effects using micron fiber diameter materials. In order to
simulate an older individual we used 6-month-old B6C3F1 mice and examined both innate and
acquired immune responses following in vivo exposure to electrospun polycaprolactone graft
material and compared effects of nano and micron fiber diameters on the immune responses.
Specific aims 2-4 were developed to test the hypothesis that in vivo exposure to dexamethasoneloaded electrospun polycaprolactone will dose-responsively cause suppression of local joint and
footpad swelling in mouse inflammatory models with minimal systemic immunosuppression.
Specific aim 2 was to determine doses to be used in acute and systemic inflammatory models
using the acquired immune model of delayed-type hypersensitivity in response to C. albicans.
Specific Aim 3 was to determine the dose-response and time-course effects of dexamethasone
(DEX) loaded EPCL (DEX-EPCL) in the acute inflammatory model keyhole limpet hemocyanin
(KLH). Specific Aim 4 was to determine dose-response and time-course effects of
dexamethasone (DEX) loaded EPCL (DEX-EPCL) in a mouse model of rheumatoid arthritis:
collagen-induced arthritis (CIA). Additionally, the CIA model was developed in the B6C3F1
mouse strain.

Establishing Scaffolds
EPCL was chosen based on results by Smith et al. that a 50:50 blend of PDO:PCL was
immunosuppressive in the Mishell Dutton assay, an in vitro test of humoral immunity [Smith et
al. 2007]. Additionally, by choosing a single synthetic polymer the question of the role of fiber
size was more easily addressed without a protein component or multiple polymers adding
covariables. In order to test whether fiber diameter would play a role in immunotoxicity of EPCL
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scaffolds, the concentration of polymer was varied and fiber sizes of resulting scaffolds were
measured using ImageJ (NIH) software. Results shown in Figure 1 demonstrate that with a low
concentration of 50 mg/mL PCL electrospraying occurred, with a high concentration of 250
mg/mL large fused fibers occurred, primarily nanofibrous scaffolds resulted with a concentration
of 80 mg/mL and microfibrous scaffolds resulted with a concentration of 200 mg/mL.
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Figure 1. Nanofibrous and microfibrous EPCL scaffolds were achieved by varying
polycaprolactone concentration.
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CHAPTER 3: Immunotoxicological Investigation in Young Animals

The following manuscript has been published in Biomedical Materials. The work demonstrates
the lack of effect on innate, humoral, and cell-mediated immune endpoints following in vivo
implantation of EPCL in young mice.
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Abstract
Electrospun polycaprolactone (EPCL) is currently being investigated for use in tissue
engineering applications such as vascular grafts. However, the effects of electrospun polymers
on systemic immune responses following in vivo exposure have not previously been examined.
The work presented evaluates whether EPCL in either a microfibrous or nanofibrous form affects
innate, humoral, and/or cell-mediated immunity using a standard immunotoxicological testing
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battery. Holistic in vivo endpoints examined include the antibody-forming cell assay (AFC or
Plaque Assay) and the delayed-type hypersensitivity (DTH) response to C. albicans. In addition,
natural killer cell cytotoxic activity was assessed using an ex vivo assay and splenic cell
population phenotypes were analyzed by flow cytometry for material exposure-related changes.
Results indicated that 28-day subcutaneous implantation of EPCL, either in microfibrous or
nanofibrous forms, did not affect the systemic functions of the immune system in 12-16 week old
female B6C3F1 mice.

Introduction
Electrospinning is being utilized by many researchers because it has proven to be a cost
effective, relatively easy method to create complex three-dimensional tissue-engineered
structures, with specific mechanical properties, and with fiber sizes in the micron down to the
nanometer range. Native extracellular matrix (ECM) fibers are on the order of 50-500 nm, a size
that researchers strive to replicate. The advent of electrospinning biomaterials has attracted
many researchers to use the technology because it allows for the creation of small ECM sized
fibers; where previous technology allowed only for fiber diameters down to 10 µm [Boland et al.
2004a]. Although electrospun polymers are being widely investigated for use in many
biomedical applications, the immunomodulatory effects of electrospun biomaterials implanted in
vivo have not been comprehensively examined. Previously, in vitro studies of electrospun
materials have shown effects on both the innate and acquired immune responses [Smith et al.
2009, Smith et al. 2010]. The current work is the first to evaluate in vivo effects on the immune
system by an electrospun synthetic polymer, polycaprolactone (PCL). Additionally, the potential
role of fiber diameter in the toxicity of electrospun materials was examined. To this end, the
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studies presented herein were designed to evaluate the potential dose-responsive effects of
microfibrous and nanofibrous electrospun polycaprolactone (EPCL) on the innate and acquired
immune system following in vivo subcutaneous (s.c.) implantation. The approach utilized was a
standard immunotoxicological testing battery as recommended by Luster et al. using wellknown, validated assays that have been shown to be sensitive to detecting immunomodulatory
effects [Luster et al. 1988, Luster et al. 1992].
Polycaprolactone has potential for use in many soft tissue applications due to its many
favorable properties. Polycaprolactone is a synthetic biodegradable polymer that is
semicrystalline, has a low melting point (59-64°C), high solubility, and low glass transition
temperature (-60°C). PCL is degraded by hydrolysis though cleavage of ester bonds similar to
the degradation of other biodegradable polymers, such as poly(lactic acid) and poly(glycolic
acid), but at a comparatively slow rate of over one year. PCL can be used to easily form
copolymers, which allows for the manipulation of various properties [Kohn et al. 2004]. PCL has
been studied in basic toxicological studies for use in an implantable contraceptive device (the
Capronor system) without any systemic toxic effects observed [Pitt 1990]. The local and
inflammatory responses to biomaterials are very important to characterize. To this end, several in
vivo and in vitro studies have been conducted to evaluate the inflammatory response to
nanofibrous polycaprolactone and have shown an inflammatory response does occur with fibrous
capsule formation regardless of topographical structure [Giavaresi et al. 2006]. However, the
goal of the work presented in this manuscript was to evaluate the systemic immune response to
EPCL.
EPCL is currently being investigated for use in cartilage, bone, urologic, nerve, and
vascular tissue engineered constructs [Alves da Silva et al. 2010, Fang et al. 2010, Kundu et al.
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2011, Hong and Kim 2010, McClure et al. 2010]. Surprisingly, even though EPCL is being
investigated extensively for a large range of applications, little work has been done to evaluate
immune responses outside of biocompatibility assays, which are typically in vitro tests, which
are not holistic. Biocompatibility as defined by Williams is a term meant for a material used in a
specific application even though the term is often used as general material property [Williams
2003]. PCL is generally considered biocompatible and nontoxic due to studies conducted for its
use in a contraceptive device (the Capronor system, an inch long tube of PCL filled with
levonorgestrel [Hypotenuse 1988]). However holistic evaluation of PCL electrospun with micron
or nanofibers has not previously been extensively evaluated following in vivo implantation [Pitt
1988]. PCL was chosen for evaluation in these studies based on previous finding by Smith et al.
that a 50:50 blend of polydioxanone and PCL was immunosuppressive in the Mishell-Dutton
assay [Smith et al. 2007]. Additionally, a single polymer was chosen in order to test if fiber size
would impact immunotoxicity based on results by Boland et al. that demonstrated improved
biocompatibility test results with poly(glycolic acid) electrospun scaffolds with smaller mean
fiber diameters and results of Sanders et al. showing that smaller diameter polymer fibers had
reduced fibrotic capsule thickness [Boland et al. 2004b, Sanders et al. 2000]. It should be noted
the mean fiber diameter of the “nanofibrous” implants does not meet the prevalent definition of a
nanomaterial, which as defined by the EU is less than 100 nm [Liden 2011]. However, individual
fiber diameters vary and the terms nanofibrous and microfibrous have been used to differentiate
between the form with fiber diameters predominately above one micrometer and the form with
fibers predominately less than one micrometer. In addition, the less than 100 nm definition for
nanomaterials has been controversial and yet to be formally adopted by regulators outside of the
EU [Liden 2011].
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The literature provides few reports on EPCL with respect to immune function. Wolfe et
al. evaluated acute monocyte tissue factor (TF) expression in vitro for silk, EPCL, electrospun
PDO, e-PTFE by an In-Cell western assay [Wolfe et al. 2010]. Results demonstrated low levels
of TF expression for EPCL and suggested that EPCL is unlikely to cause greater risk of acute
thrombotic occlusion as compared to e-PTFE, which is currently used clinically in vascular
replacement applications. Williamson et al. evaluated human vascular endothelial cell
attachment, proliferation, and bioactivity in vitro with an electrospun composite of PCL and
polyurethane [Williamson 2006]. Results indicated that endothelial cells attached to the PCL
surface forming a monolayer, proliferate, and normally release von willebrand factor and nitric
oxide. Nottelet et al. were able to successfully replace the abdominal aorta in Sprague-Dawley
rats with an EPCL graft. Their findings, after 12 weeks of implantation, were that the grafts were
patent and fully endothelialized (however with some intimal hyperplasia) and that cellular
infiltration by macrophages and fibroblasts had occurred [Nottelet et al. 2009]. Overall, these
studies suggest that EPCL has excellent blood compatibility and cytocompatibility, however no
conclusions regarding its immunocompatibility can be drawn.
The immune system, with innate and acquired (cell mediated and humoral) immunity, is
composed of cells, organs, and soluble factors which protect the body from foreign and
infectious agents. Innate immunity includes the skin, phagocytic cells (such as macrophages and
polymorphonuclear cells (PMN)), natural killer (NK) cells, and various soluble factors including
those of the complement system. Innate immunity is the first defense against pathogens but is not
specific to the pathogen. Acquired immunity is divided into cell-mediated immunity (T cell) and
humoral immunity (B cell/antibody-mediated). Acquired immune responses are specific to the
pathogen (antigen) but are slower to respond. Each component of the immune system has a
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specific function, yet all parts are integrated with each other and with other organ systems,
including the endocrine and nervous systems. Inappropriate modulation of the immune system
can result in immunosuppression and decreased ability of the host to defend itself against
pathogens. Alternatively, an enhanced response to “self” antigens can result, which may lead to
the formation of autoimmunity [Janeway 2008].
The work presented evaluates the potential of both microfibrous and nanofibrous EPCL
to produce immunomodulatory effects following 28 days of exposure in vivo in 12-16 week old
female B6C3F1 mice. Splenocyte phenotypic changes were evaluated using flow cytometry, and
innate immunity was assessed using the natural killer cell activity assay. To assess effects on
humoral immunity, the holistic measure of the T-dependent antibody response (AFC assay) and
the sheep red blood cell (sRBC) ELISA were used. Finally, cell-mediated immunity was
evaluated using the holistic delayed-type hypersensitivity response.

Materials and Methods
Scaffold Preparation
PCL (molecular weight 65 000 kDa, Sigma-Aldrich) was dissolved in 1,1,1,3,3,3hexafluoro-2-propanol (HFP; TCI America) at concentrations of 80 mg/mL and 200 mg/mL for
nanofibrous and microfibrous scaffolds, respectively. In order to obtain equal thickness
(approximately 0.3 mm), 8 mL was used for nanofibrous and 2 mL for microfibrous scaffolds.
Using a KD Scientific syringe pump, solutions were dispensed at 8 mL/h (from a 10 mL syringe
for nanofibrous and a 3 mL syringe (Becton Dickinson) for microfibrous with an 18 gauge blunt
tip needle) and electrospun onto a rectangular mandrel (7.7 cm x 3.2 cm x 30.5 cm). A fixed
voltage of 25 kV was applied to the needle by a Spellman CZE1000R high voltage power supply
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(Spellman High Voltage Electronics Corp., Hauppauge, NY). The grounded mandrel had a
rotational speed of 500 rpm and translational speed of 2 cm/s over a translational distance of
±3.75 cm. Circular pieces 6 mm diameter (representing 32 mm2 surface area) were punched
using a single hole paper punch (Harold’s Business Supply, Richmond, VA) and then disinfected
in 100% ethanol for 30 min followed by three 10-minute washes in physiological saline.

Scanning Electron Microscopy
Representative samples were sputter-coated with gold (Model 5550; Electron Microscope
Sciences) and scanning electron microscopy (SEM, Zeiss EV050) was used to obtain
micrographs. Micrographs were analyzed to determine fiber size using ImageJ (NIH) by taking
80 random measurements from throughout the image and obtaining the mean and standard error.

Animal Husbandry and Exposure
All animal procedures were conducted under an animal protocol approved by the
Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University
(VCU). Female B6C3F1 (Taconic Farms) were housed four per cage, and started on study
between 12-16 weeks old. Animals were fed NTP 2000 diet and provided tap water ad libitum.
Vivarium conditions were maintained at 21-24°C and 40–70% relative humidity, with a 12-h
light/dark cycle. Mice were determined to be free of M. pulmonis, coronavirus, and Sendai virus
by murine Immunocomb test kits (Charles River). Following randomization, eight mice were
assigned to each dose group. For each implant, a small incision (approximately 1 cm) was made
on the ventral side below the zyphoid process and above the acetabulofemoral joint. By blunt
dissection using Miltex 18-780 forceps (Thomas Scientific, Swedesboro NJ) a small pocket was
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prepared s.c. to insert the material. The incision sites were closed using surgical staples. The low
dose animals received 1 implant (total surface of 32 mm2), the middle dose received 2 implants
(64 mm2), and the high dose 4 implants (128 mm2). Sham (negative control) animals received
the same surgical manipulations as the high dose animals, however they did not receive any
implants. Animals were administered lidocaine topically (lidocaine has been tested in the
laboratory and shown to have no effect on the holistic AFC and IgM ELISA response to sRBCs
following 3 days of exposure) on each incision site daily for 3 days after surgery, and staples
were removed on or after 5 days following surgery. During this postoperative period, animals
were closely monitored for signs of infection with no infections encountered during the studies.

Toxicological Studies
Animal body weights were obtained at the start and end of study to determine the effects
of EPCL on body weight. When the endpoint required the excision of the spleen, the spleens
were excised and weighed. In addition, a study was conducted for each form of EPCL where the
thymus, lungs, liver, spleen, and kidneys with adrenals were excised and weighed and evaluated
as both absolute and percent of body weight.

Splenocyte Single-cell Suspension Preparation
On day 29 of implantation, mice were anesthetized by CO2 inhalation and then
euthanized by cervical dislocation. Spleens were excised and placed in 3 mL of Earle’s Balanced
Salt Solution (EBSS) with 15 mM HEPES (GibcoBRL, Grand Island, NY, USA). Splenocyte
suspensions were prepared by mincing the spleen between the frosted ends of two microscope
slides, washing the slides with media and then returning all of the suspension to 5 mL test tubes.
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Samples were centrifuged at 300g for 10 min and resuspended in RPMI 1640 (GibcoBRL, Grand
Island, NY, USA) complete medium with 10% fetal bovine serum (Hyclone). Cell counts were
determined using a ZBII Coulter® counter in the presence of ZAP-OGLOBIN II lytic reagent
(Coulter Corporation, Miami, Florida).

Positive Controls
Cyclophosphamide (CPS, Sigma-Aldrich) at a concentration of 50 mg/kg in phosphate
buffered saline (PBS) was given to animals on the last 4 days of the exposure period by
intraperitoneal (i.p.) injection as a positive control for the AFC assay, DTH response, and
splenocyte phenotypic analysis, and spleen and thymus weights. Rabbit anti-asialo GM1
(AAGM1, Wako BioProducts, Richmond, VA) was administered by intravenous (i.v.) injection
(0.2 mL) after a 1:10 dilution in sterile physiological saline on day 28 as positive control for the
natural killer cell activity.

Natural Killer Cell Activity
Natural killer cell activity was assessed using a modified version of the assay described
by Reynolds and Herbman [Reynolds and Herbman 1981]. The positive control group received
anti-asialo GM1 (0.2 mL at a 1:10 dilution) i.v. once on day 28. Splenocyte suspensions,
effector cells, were adjusted to 1x106 cells/mL. T cell lymphoma YAC-1 cells, target cells, were
labeled with 51Cr and diluted to 1x105 cells/mL. In a 96-well plate, 0.1 mL of effector cells and
then 0.1 mL of target cells were added to yield six target:effector cell ratios (200:1, 100:1, 50:1,
25:1, 12.5:1, 6.25:1) with two replicates per ratio for each animal. Twelve wells with target cells
only received either medium or Triton X-100 for measurement of spontaneous and maximum
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release, respectively. After a four-hour incubation, plates were centrifuged at 250g for 10 min
and 0.1 mL of supernatant was removed from every well and counted on a Wallac 1480
Wizard® 3” gamma counter (Perkin Elmer, Turku, Finland). Percent cytotoxicity was then
determined as the difference of the experimental and spontaneous releases divided by the
difference of the maximum and spontaneous releases. The natural killer cell activity assay was
conducted once for each form of EPCL [Reynolds and Herbman 1981].

Antibody Forming Cell Assay
A modified version of the Jerne and Nordin hemolytic plaque assay was used to measure
the primary IgM antibody-forming cell (AFC) response to sheep red blood cells (sRBC) as
described by White et al. [Jerne and Nordin 1963, White et al. 2010]. Positive control animals
received CPS given i.p. on days 25- 28. Mice were immunized i.v. 4 days prior to sacrifice with
7.5x107 sRBCs. Splenocyte suspensions were prepared in EBSS and an aliquot of cells was
added to a test tube containing guinea pig complement, sRBC and warm agar (46–48°C). The
mixture was placed in a petri dish, covered with a microscope cover slip and incubated at 37°C
for 3 hours. Cell counts were performed, and the developed plaques were counted using a
Bellco® plaque viewer. The data were expressed as specific activity (AFC/106 spleen cells) and
total activity (AFC/spleen).

sRBC ELISA
The IgM enzyme-linked immunosorbent assay (ELISA), as previously described by
Temple et al., was used to determine primary IgM serum titers to sRBC from the same animals
used in the plaque assay [Temple et al. 1993]. At the time of sacrifice, blood was obtained by
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cardiac puncture via 1 mL syringes (Becton Dickinson) with 23 gauge needles and place into
borosilicate glass tubes to clot. After at least 2 hours of clotting, the serum was collected.
Briefly, the day before the assay was conducted Immulon-2® microtiter plates were coated with
100 µl (5 µg/mL/per well), of sRBC membrane preparation containing high-salt release antigens
and incubated at 4°C. Between steps plates were washed with 0.01% Tween 20 in PBS. Serum
from each animal was diluted (1:8 or 1:2 for positive controls) in the Tween/PBS buffer and after
blocking 100 µl of the serum was added to each well with 100 µl of buffer. Each serum sample
was assayed as 10 serial two-fold dilutions. Plates were incubated for 1 hour at room
temperature and 100 µl of horseradish peroxidase-conjugated anti-mouse antibody (Southern
Biotech, Birmingham, AL) was added and plates were incubated for an additional 1 hour.
Finally, peroxidase substrate (2,2’-azino-di[3-ethyl-benzthiazoline-6-sulfonic acid]) (SigmaAldrich) was added and the absorbance was read after 45 min at 405 nm on a THERMOmaxTM
microplate reader (Molecular Devices Corp., Sunnyvale, CA). The mean absorbance was
obtained using SoftMax® Pro (Molecular Devices Corp., Sunnyvale, CA) by comparison with
the linear portion of the standard curve to find the value at 0.5 optical density (OD). Titers are
defined as the reciprocal of the serum dilution that has an OD value of 0.5, and were determined
for each animal. One sRBC ELISA was done for each form of EPCL.

Delayed-Type Hypersensitivity Assay
The DTH assay was measured in response to Candida albicans, as described by Smith
and White [Smith and White 2010]. On day 21 following surgery, mice were sensitized with
1x107 formalin fixed Candida albicans organisms by s.c. injection (100 µl into the right flank. A
challenge only negative control group remained unsensitized. On day 29, all animals were
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challenged by injection of 40 µl (1.1 mg/mL) of Candida albicans chitosan antigen in the right
footpad. Prior to the challenge, a pre-challenge measurement was taken of the right foot using a
digital micrometer (Mitutoyo Corp., Tokyo, Japan). Twenty-four hours later, the thickness of the
right footpad was measured. The mean change in footpad thickness was calculated for each
mouse (post-challenge minus pre-challenge thickness) and was expressed as footpad swelling in
mm x 100. The DTH was conducted twice for both microfibrous and nanofibrous EPCL.

Flow Cytometric Analysis
The percentages and total number of lymphocyte subsets in the spleen were measured
using flow cytometric analysis in a single set of animals (n=8) for microfibrous and nanofibrous
EPCL [Guo et al. 2001]. All antibodies used were obtained from BD Pharmingen (San Diego,
CA., USA) and diluted 1:80 in staining buffer. Antibodies used were rat anti-mouse CD4–PE,
anti-mouse CD8a– FITC, anti-mouse CD3– FITC, anti-mouse CD25–FITC, anti-mouse NK1.1PE, and anti-mouse Mac3-FITC. Splenocyte suspensions were labeled in the presence of antiCD16/32 (Mouse FC block) for 30 min on ice. Following initial staining with antibody and
washing with staining buffer, propidium iodide (PI, Sigma-Aldrich) solution was added (nonviable cell label). A Becton Dickinson FACScan® Flow Cytometer was used for enumeration
where log fluorescence intensity was read gated on PI (100µL of 0.005 mg/mL) to eliminate
dead cells. A forward scatter threshold high enough to eliminate red blood cells was used. Data
were analyzed using CellQuestTM software (Becton Dickinson, San Jose, CA). Isotype-matched
irrelevant antibodies were used as controls.
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Statistical Analysis
Data were evaluated by using a parametric one-way analysis of variance (ANOVA). The
Dunnett’s t-Test, a post hoc comparison test, was used to compare and determine differences
between the treatment and sham control groups.

Results

Fiber Size
As seen in Figure 2, scanning electron micrographs of EPCL showed that scaffolds with
micron diameter fibers (left panel) and submicron diameter fibers (right panel) were achieved by
modifying the concentration of the polymer solution. As measured, the mean fiber diameter with
a concentration of 200 mg/mL of PCL (microfibrous) was 1.7±0.1 µm while with a concentration
of 80 mg/mL of PCL (nanofibrous) the mean was 0.23±0.03 µm.

Figure 2. Scanning electron micrographs of electrospun polycaprolactone with micron diameter
fibers (left panel) and submicron diameter fibers (right panel) achieved by modifying the
concentration of the polymer solution. The mean fiber diameter with a concentration of 200
mg/mL of PCL is 1.7±0.1 µm with a concentration of 80 mg/mL of PCL the mean is 0.23±0.03
µm.
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Effect of EPCL on Body and Organ Weights
Subcutaneous implantation of microfibrous or nanofibrous EPCL for 28 days had no
effect on body weights in 12-16 week old B6C3F1 mice (data not shown). No overt signs of
toxicity or mortalities occurred. Organ weight measurements were evaluated as both absolute
organ weights and organ to body weight ratio (relative weights) for the liver, spleen, lung,
thymus, and kidneys with adrenals. Organ weights were evaluated in animals also used for the
AFC study therefore spleen weights are slightly increased for all groups due to immunization
with sRBC as compared to unimmunized animals. No significant differences were observed
between the sham controls and EPCL implanted animals for any organs evaluated.

Effect of EPCL on Splenocyte Phenotype
As shown in Table 1, following analysis by flow cytometry, microfibrous EPCL did not
affect percentages of B cells, T cells, or macrophages at any dose level. The percent of natural
killer cells was slightly increased with both 1 (10% increase) and 4 implants (8% increase). The
percentage of macrophages was decreased (21%) in the same study for the naïve control. With 4
implants, the absolute numbers of T cells, T cell subsets, B cells, and NK cells increased, and
with 1 implant, the absolute number of NK cells was increased. However, in this study, the total
number of spleen cells was increased with 1 and 4 implants, therefore it is not surprising that
absolute numbers of spleen cell subsets were increased as well. Because the increase in cell
numbers observed in this single study is inconsistent with other studies, these effects are not
believed to be biologically relevant.
As seen in Table 2, nanofibrous EPCL did not affect the percentage of T cells at any dose
level. The percentage of B cells was slightly increased with 1, 2, and 4 nanofibrous implants
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when compared to sham control, however, the sham control in the study had a slightly lower
percentage of B cells than both the naïve group and historical controls. The total spleen cell
number was decreased in the study with one implant and therefore decreases were seen in the
absolute number of spleen cell subsets (CD8, NK, macrophages). The absolute number of NK
cells was decreased with 1, 2, and 4 implants, and % NK cells was decreased with 1 and 4
implants only. The results do not demonstrate dose-responsive changes in phenotypic markers
and are not believed to be biologically relevant. Naïve controls in the nanofibrous study had
decreased NK cell numbers (24%) and decreased macrophage numbers (22%) compared to the
sham control. As expected, in both studies, CPS-treated animals had increased T cell and
macrophage numbers and decreased absolute T, T subset, and NK numbers. Anti-asialo GM1
exposed animals had minimal numbers of NK cells.
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Table 1. Splenocyte subsets following microfibrous EPCL implantation. Results are presented as mean ± S.E. for absolute or
percent cells. The level of statistical significance is denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group. N/C =
not conducted. Only appropriate positive controls were used for each cell type.
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Table 2. Splenocyte subsets following nanofibrous EPCL implantation. Results are presented as mean ± S.E. for absolute or
percent cells. The level of statistical significance is denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group. N/C =
not conducted. Only appropriate positive controls were used for each cell type.
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Effect of EPCL on Innate Immunity: NK Cytotoxicity
Results are shown as percent cytotoxicity (Figure 3). Neither microfibrous or
nanofibrous EPCL had effects on natural killer cell activity in 12-16 week old female B6C3F1
mice. As expected, animals that received AAGM1 had minimal cytotoxicity as compared to
sham control. In the nanofibrous EPCL study, percent cytotoxicity in the naïve group was lower
than for the sham at five of the six effector:target ratios (all except 200:1), the reason for this is
unclear, however the appropriate control group for the NK study was the sham control group.
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Figure 3. Natural Killer cell activity. Results are presented as mean ± S.E. for percent cytotoxicity. The level of statistical
significance is denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group.
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Effect of EPCL on Humoral Immunity: AFC
The results are presented as AFC/106 spleen cells (specific activity) and total spleen
activity. As shown in Figures 4 and 5, neither microfibrous or nanofibrous EPCL significantly
affected the AFC response to sheep erythrocytes on either specific activity or total spleen activity
in 12- 16 week old female B6C3F1 mice. Results represent the percent control mean obtained
from combining three studies, each of which utilized seven or eight animals per group. Since the
comparisons of sham control means between three studies conducted were found to be
significantly different, the studies were combined and presented as percent control. CPS
significantly suppressed the AFC response as expected.
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Figure 4. Spleen IgM Antibody-Forming Cell (AFC) Response to Sheep Erythrocytes. Female B6C3F1 mice were exposed to
microfibrous of nanofibrous EPCL for 28 days and were immunized with sRBCs on day 25. Results are presented as percent control
mean ± S.E. for the AFC/106 Spleen Cells (specific activity) and AFC/Spleen (total spleen activity). Results represent the mean
obtained from combining three studies, each of which used seven or eight animals per group. Comparisons of sham controls means
between three studies were conducted using ANOVA 243 ± 21 vs. 290 ± 58 vs. 293 ± 55 for specific activity and 1401± 76 vs. 1767 ±
242 vs. 1036 ± 198 for total spleen activity. On days 25-28, 50 mg/kg cyclophosphamide (CPS) was administered as a positive control
by i.p. injection. The level of statistical significance is denoted as ** p < 0.01 as compared to the sham control group.
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Figure 5. Spleen IgM Antibody-Forming Cell (AFC) Response to Sheep Erythrocytes. Female B6C3F1 mice were exposed to
microfibrous of nanofibrous EPCL for 28 days and were immunized with sRBCs on day 25. Results are presented as percent control
mean ± S.E. for the AFC/106 Spleen Cells (specific activity) and AFC/Spleen (total spleen activity). Results represent the mean
obtained from combining three studies, each of which used seven or eight animals per group. Comparisons of sham controls means
between three studies were conducted using ANOVA 753 ± 69 vs. 261± 12 vs. 290 ± 58 for specific activity and 3077 ± 268 vs. 1322
± 46 vs. 1036 ± 198 for total spleen activity). On days 25-28 50 mg/kg cyclophosphamide (CPS) was administered as a positive
control by i.p. injection. The level of statistical significance is denoted as **p < 0.01 as compared to the sham control group.
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Effect of EPCL on Humoral Immunity: sRBC Primary IgM ELISA Response
sRBC ELISA results are expressed as mean Log2(Titer) as shown in Figure 6.
Consistent with the AFC results, neither microfibrous or nanofibrous EPCL produced any
significant effects compared to the sham control. Positive control mice, which received CPS, had
a significant decrease in the serum IgM response to sRBC compared to the sham control.
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Figure 6. sRBC ELISA. Results are presented as Titer (Log2) Mean ± S.E. Level of statistical significance is denoted as ** < p 0.01
as compared to the sham control group.
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Effect of EPCL on Cell-mediated Immunity: DTH
The DTH results are presented as mean footpad swelling (Figure 7). Subcutaneous
implantation of microfibrous or nanofibrous EPCL did not affect the DTH response to C.
albicans in 12-16 week old female B6C3F1 mice. As expected, footpad swelling of the challenge
only group was significantly different from the sham control group, which had received both
sensitization and challenge. CPS, the positive control, significantly suppressed the footpad
swelling when compared to the sham control.
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Figure 7. Delayed type hypersensitivity response to C. albicans. Results are presented as Mean ± S.E. footpad swelling (mm*100).
Level of statistical significance is denoted as ** p < 0.01 as compared to the sham control group.
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Discussion
This work represents the first comprehensive in vivo evaluation of an electrospun
polymer for immunotoxicological effects, evaluating the three major components of the immune
response. Previously, electrospun polymer blends (PDO:elastin and PDO:collagen) have been
evaluated in vitro by Smith et al. [Smith et al. 2009, Smith et al. 2010]. Both PDO:elastin and
PDO:collagen blends produced effects on innate, humoral, and cell-mediated immunity in vitro
as described below.
The synthetic polymer silicone has been studied extensively in multiple forms (gel,
elastomer, fluid, with polyurethane cover) for immunotoxicological effects following in vivo
exposure by s.c. implantation. Results from these studies indicated that silicone (and
polyurethane covered silicone) did not affect any endpoint tested, with the exception of NK cell
activity, which was decreased with the silicone gel. However, the authors indicated the decrease
was minimal, inconsistent and was not considered to contraindicate the use of silicone gel in
implant materials [Bradley et al. 1994, NTP 1992].
Smith et al. assessed electrospun PDO:elastin and PDO:collagen in vitro for effects on
innate immunity using the NK assay, macrophage phagocytosis, ROS production, and nitric
oxide production [Smith et al. 2009, Smith et al. 2010]. Natural killer cell activity was
significantly suppressed following exposure to both PDO:elastin and PDO:collagen blends in
vitro, while other endpoints were unaffected. Following in vivo exposure to EPCL neither
microfibrous or nanofibrous EPCL affected NK activity. Although naïve controls differed from
sham controls when nanofibrous EPCL was evaluated for NK activity, this was not repeated in
the microfibrous study and does not appear to be biologically significant.
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Effects on humoral immunity were also assessed for PDO:elastin and PDO:collagen
blends by Smith et al. using the Mishell-Dutton assay—the in vitro analogue to the AFC assay
[Smith et al. 2009, Smith et al. 2010]. Blends of both PDO:elastin and PDO:collagen
significantly suppressed the number of antibody forming cells per culture. Additionally, Smith et
al. found that a 50:50 blend of PDO:PCL significantly suppressed humoral immunity in the
Mishell-Dutton assay [Smith et al. 2007]. In contrast, the present findings showed that
electrospun PCL does not suppress humoral immunity in either the AFC assay or the IgM serum
ELISA.
Cell-mediated immunity was evaluated in vivo using the DTH response to C. albicans,
which is a holistic functional assay. Following exposure to microfibrous and nanofibrous PCL,
no effects were observed on footpad swelling, the endpoint of the DTH response. This assay has
been indicated to be more sensitive than ex vivo assays (such as the MLR or cytotoxic T
lymphocyte [CTL] assay) [Smith et al. 2011, White et al. 2012]. In contrast, Smith et al. have
previously found that in vitro exposure to PDO:elastin and PDO:collagen blends affected both T
and B cell proliferation using lymphoproliferative assays (MLR, F(ab’)2, anti-CD3) [Smith et al.
2009, Smith et al. 2010]. No biologically significant differences occurred in splenocyte
phenotypes when evaluated for both microfibrous and nanofibrous EPCL exposure in vivo.
Although sporadic differences did occur, none of these changes were dose-responsive and
therefore are not believed to be biologically relevant. Functional holistic assays also confirm the
lack of biological effect on these cell types.
Although Smith et al. evaluated different polymers and blends, those works suggested
that electrospun polymers could be immunosuppressive. The work presented here was conducted
in order to evaluate the dose-response effects of a single electrospun polymer following in vivo
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exposure as opposed to in vitro. When converted based on percent surface area (SA) a single
implant would have an equivalent surface area of 6800 mm2, or a circular disc with a diameter of
9-cm in humans. Therefore, the highest dose tested (four 6 mm implants in the mouse) would be
equivalent to four 9 cm implants in a human. This level of exposure is relevant for many
potential applications for EPCL. For example, this exposure level (approximately 272 cm2 SA)
would comparable to vascular graft with 4 mm inner diameter that is 2 m long. All results
suggest that neither microfibrous or nanofibrous EPCL suppress innate, humoral, or cellmediated immunity and that EPCL appears to have excellent immunocompatibility.

Conclusions
Although testing of local and inflammatory response are routinely conducted for
biomaterials, potential effects on the systemic immune system are not often tested. The work
presented is the first immunotoxicological evaluation of an electrospun polymer in vivo. These
findings show that both microfibrous and nanofibrous EPCL had no biologically significant
effects on any of the parameters examined. Although other endpoints, such as the mononuclear
phagocytic system, remain to be evaluated, this work represents a promising start to obtaining
more in-depth assessments of the in vivo immunocompatibility and safety of electrospun
polymers. In addition, in this work, no difference was observed between microfibrous and
nanofibrous materials, thereby suggesting that neither configuration for EPCL biomaterials is
more immunotoxic than the other. EPCL therefore is a material with excellent
immunocompatibility deserving further investigation for tissue engineering applications.
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CHAPTER 4: Immunotoxicological Investigation in Aged Animals
The following manuscript has been prepared for submission to Food and Chemical Toxicology.
The work demonstrates the lack of effect on innate, humoral, and cell-mediated immune
endpoints following in vivo implantation of EPCL in aged mice.
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Abstract
Recently our laboratory reported the lack of effects on innate, humoral, and cell-mediated
immunity in young adult mice following in vivo exposure to electrospun polycaprolactone
(EPCL). Electrospinning is a polymer processing technique being widely investigated to create
scaffolds for tissue engineering. EPCL in particular has potential use in applications ranging
from vascular grafts to drug delivery. When the target population is aged, which is the case for
many of the applications for EPCL, immunosenescence can play a role in the potential
immunotoxicity of a xenobiotic. Therefore, this work evaluated the potential for EPCL in a
microfibrous and a nanofibrous to produce immunosuppressive effects in aged female B6C3F1
mice. Multiple components of innate, humoral, and cell-mediated immunity were evaluated.
Endpoints examined included the antibody-forming cell assay (AFC or Plaque Assay) and the
delayed-type hypersensitivity (DTH) response to C. albicans. An ex vivo assay of natural killer
cell cytotoxic activity was used to assess innate immunity. Additionally, spleen cell phenotypes
were analyzed by flow cytometry. All results indicated that the systemic immune functions in
24-28 week old female B6C3F1 mice were not affected following 28-day subcutaneous
implantation of EPCL in either in microfibrous or nanofibrous form.

Introduction
Electrospinning is a popular polymer processing technique often used to create scaffolds
for tissue engineering applications. We have previously reported the lack of effect following
subcutaneous implantation of a synthetic electrospun polymer, electrospun polycaprolactone
(EPCL), in both microfibrous and nanofibrous form, in young adult B6C3F1 mice [McLoughlin
et al. 2012]. These results were in contrast to the work of Smith et al. that showed
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immunomodulatory effects on both innate and acquired immunity following in vitro exposure of
mouse spleen cells to electrospun materials [Smith et al. 2010, Smith et al. 2009].
Aging causes significant changes in both the innate and acquired immune systems. With
age, hematopoietic stem cells, which give rise to B cells, T cells, and NK cells, have decreased
function and ability to differentiate into immune cells. Macrophages and neutrophils show a
decline in phagocytic capability with age, while NK cells increase in number but decrease in
their ability to kill tumor cells and virally infected cells. Furthermore, cytokine and chemokine
production is altered and it has been suggested that macrophages and fibroblasts produce more
pro-inflammatory cytokines. Lower numbers of pro- and pre-B cells are seen in the aged immune
system, and antibodies produced by B cells have lower affinity. Naïve T cells tend to have
reduced ability to proliferate and defects in cytokine production. Memory T cells developed
when animals are young continue to function well, but memory T cells originating from older
animals have decreased responses. With these significant changes the immune system of old
animals needs to be evaluated separately from that of young adult animals [Aw et al. 2007].
Although differential susceptibility of the developing immune system [Burns-Naas et al.
2008] is often investigated, the role of the aged immune system in xenobiotic immunotoxicity
has been largely unexplored. Oughton et al. evaluated phenotypic changes of immune cells in the
spleen and blood in aged mice alongside a study of long-term exposure to tetrachlorodibenzo-pdioxin (TCDD). Results demonstrated age-related increases in effector and memory T cells and
fewer naïve T cells in both the spleen and peripheral blood as well as decreases in the number of
CD4+ T cells. In spite of thymic involution, changes in thymic cell phenotypes did not occur
[Oughton et al. 1995]. Duffy et al. examined age related differences in immune responses to
polychlorinated biphenyl (PCB) exposure in Japanese medaka fish. Specifically, the authors
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reported that juvenile fish were more susceptible to PCB-induced effects on innate immunity
(superoxide production), however age-related differences in humoral immunity (AFC response)
were not as prevalent [Duffy et al. 2002, Duffy et al. 2003]. Studies by Luebke et al. and Vos et
al. have shown that, following TCDD and bis(tris-n-butyltin) oxide (TBTO) exposure in aged
animals, the aged immune system can provide protection from parasite infection when the
clearance is T cell dependent [Luebke et al. 1999, Vos et al. 1990]. However, Luebke et al. have
shown that the difference in susceptibility to increased or decreased host resistance due to age is
model dependent, as aged animals may be more susceptible than young when humoral immunity
plays a greater role [Luebke et al. 2000]. Dortant et al. explored age-related differences between
young adult (12 week old) and old (27-30 month old) SPF wag rats following exposure to
Ochratoxin A (OTA). The authors found similar kidney and brain toxicity profiles in both age
groups, determined the old rats were more susceptible than young rats to OTA exposure based on
clinical and pathological data, and finally concluded that the immune system is not the primary
target of OTA [Dortant et al. 2001].
The lack of immunotoxicity with EPCL in young animals was an important finding
toward the potential for using such electrospun tissue engineered devices in a clinical setting.
However, if a tissue engineering product’s intended patient population is elderly with potential
age-related immunosenescence, the material’s potential to produce immunosuppression in this
population needs to be addressed. The work presented herein was undertaken to test the
hypothesis that EPCL in a microfibrous or nanofibrous form would cause immunosuppressive
effects in aged mice. Validated assays were chosen that have been shown to be sensitive for
detecting immunomodulatory effects in a similar manner to the immunotoxicological testing
battery approach suggested by Luster et al. [Luster et al. 1988, Luster et al. 1992].
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As previously reported, EPCL was prepared in microfibrous and nanofibrous form by
modifying the concentration of the polymer solution [McLoughlin et al. 2012]. Scanning electron
micrographs were obtained and the mean fiber diameters were measured using ImageJ software
(NIH). Microfibrous EPCL had a mean of 1.7±0.1 µm and nanofibrous had a mean of 0.23±0.03
µm.
The potential of both microfibrous and nanofibrous EPCL to produce immunomodulatory
effects following 28 days of exposure in vivo in 24-28 week old female B6C3F1 mice was
evaluated. Splenocyte phenotypic changes in T cells and T cell subsets, B cells, natural killer
cells, and macrophages were evaluated using flow cytometry. Innate immunity was assessed
using the natural killer cell activity assay. A holistic measure of the T-dependent antibody
response (TDAR) was conducted using the AFC assay. In addition, serum antibody levels to the
T-dependent antigen, sheep red blood cells (sRBC) were also used to assess effects on the
TDAR. Effects on cell-mediated immunity were evaluated using a holistic assay evaluating the
delayed-type hypersensitivity response to C. albicans.

Materials and Methods

Scaffold Preparation
As previously reported, PCL (molecular weight 65 000 kDa, Sigma-Aldrich) was
dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFP; TCI America) at concentrations of 80
mg/mL (nanofibrous) and 200 mg/mL (microfibrous) and scaffolds were prepared by
electrospinning [McLoughlin et al. 2012]. Implants were obtained by punching circular pieces 6
mm diameter (representing 32 mm2 surface area) using a single hole paper punch (Harold’s
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Business Supply, Richmond, VA). The implants were disinfected in 100% ethanol for 30 min
followed by three 10-minute washes in physiological saline.

Animal Husbandry and Exposure
All animal procedures were conducted under an animal protocol approved by the
Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University.
Animals were fed NTP 2000 diet, provided tap water ad libitum, and vivarium conditions were
maintained at 21-24ºC and 40–70% relative humidity, with a 12-h light/dark cycle. Sentinel
animals were tested for and found to be free of M. pulmonis, coronavirus, and Sendai virus by
murine Immunocomb test kits (Charles River). Female B6C3F1 (Taconic Farms) were housed
four per cage, and were placed on study between 24-28 weeks of age. Mice were randomized,
and eight mice were assigned to each dose group. Surgical procedures have been described
previously [McLoughlin et al. 2012]. Briefly, for each implant, a 1 cm incision was made on the
ventral quadrant and a small pocket was prepared for insertion of EPCL by blunt dissection.
Incisions were closed using surgical staples. The low dose animals were implanted with 1 EPCL
disc (total surface of 32 mm2), the middle dose received 2 discs (64 mm2), and the high dose 4
implants discs (128 mm2). Sham (negative control) animals received the same surgical
manipulations as the high dose animals, however, they did not receive any implants. Animal
body weights were obtained at the start and end of study.

Positive Controls
For the AFC assay, DTH response, and splenocyte phenotypic analysis, positive control
animals received 50 mg/kg cyclophosphamide (CPS, Sigma-Aldrich) by intraperitoneal (i.p.)
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injection on days 25-28. For the natural killer cell activity assay, positive control animals were
administered a 1:10 dilution in sterile physiological saline of rabbit anti-asialo GM1 (AAGM1,
Wako BioProducts, Richmond, VA) by intravenous (i.v.) injection (0.2 mL) on day 28.

Natural Killer Cell Activity
Natural killer cell activity was assessed using a modified version of the assay described
by Reynolds and Herbman, as previously described [Reynolds and Herbman 1981]. In 96-well
plates, splenocyte suspensions (effector cells) and 51Cr–labeled T cell lymphoma YAC-1 cells
(target cells) were incubated for four hours at six effector:target cell ratios (200:1 , 100:1, 50:1,
25:1, 12.5:1, 6.25:1) with two replicates per ratio for each animal. Twelve wells with target cells
only received either medium or Triton X-100 for measurement of spontaneous and maximum
release, respectively. After incubation, plates were centrifuged at 250g for 10 min, and 0.1 mL of
supernatant was removed from every well and counted on a Wallac 1480 Wizard® 3” gamma
counter (Perkin Elmer, Turku, Finland). Percent cytotoxicity was then calculated as
(experimental - spontaneous release) / (maximum - spontaneous releases).

Antibody Forming Cell Assay
As described by White et al. a modified version of the Jerne and Nordin hemolytic plaque
assay was used to measure the primary IgM antibody-forming cell (AFC) response to sheep red
blood cells (sRBC) [White et al. 2010, Jerne and Nordin 1963]. Mice were immunized i.v. on
day 25 with 7.5x107 sRBCs. Splenocyte suspensions were prepared in EBSS and an aliquot of
cells was added to a test tube containing guinea pig complement, sRBC and warm agar (46–
48°C). The mixture was placed in a petri dish, covered with a microscope cover slip and
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incubated at 37ºC for 3 hours. Cell counts were performed, and the developed plaques were
counted using a Bellco® plaque viewer. The data were expressed as specific activity (AFC/106
spleen cells) and total activity (AFC/spleen).

sRBC ELISA
The same group of animals that was used for the AFC assay was used to determine
primary IgM serum titers to sRBC using the IgM enzyme-linked immunosorbent assay (ELISA),
as previously described by Temple et al. [Temple et al. 1993]. At the time of sacrifice, blood was
obtained by cardiac puncture using 1 mL syringes (Becton Dickinson) with 23 gauge needles and
placed into borosilicate glass tubes to clot. After at least 2 hours, the serum was collected and
stored frozen at -20°C until thawed for analysis. Briefly, the day before the assay was conducted,
Immulon-2® microtiter plates were coated with 100 µl per well of 10 µg/mL of sRBC membrane
preparation containing high-salt release antigens and incubated overnight at 4°C. 0.05% Tween
20 in PBS was used as the assay buffer. Serum from each animal was diluted (1:8 or 1:2 for
positive controls) and each serum sample was assayed as 10 serial two-fold dilutions. The
secondary antibody used was horseradish peroxidase-conjugated goat anti-mouse IgM antibody
(Southern Biotech, Birmingham, AL) and the peroxidase substrate used was 2,2’-azino-di[3ethyl-benzthiazoline-6-sulfonic acid] (Sigma-Aldrich). After 45 min of substrate incubation at
room temperature, the absorbance was read at 405 nm on a THERMOmaxTM microplate reader
(Molecular Devices Corp., Sunnyvale, CA). The mean absorbance was obtained using
SoftMax® Pro (Molecular Devices Corp., Sunnyvale, CA) by comparison with the linear portion
of the standard curve to find the value corresponding to 0.5 optical density (OD). Titers were
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determined for each animal and are defined as the reciprocal of the serum dilution having an OD
value of 0.5.

Delayed-Type Hypersensitivity Assay
The DTH response to Candida albicans was measured as described by Smith and White
[Smith and White 2011]. On day 21 following surgery, mice were sensitized with 1x107 formalin
fixed Candida albicans organisms by s.c. injection (100 µl) into the right flank. A challenge only
negative control group remained unsensitized. On day 29, prior to the challenge, a pre-challenge
measurement was taken of the right foot using a digital micrometer (Mitutoyo Corp., Tokyo,
Japan). All animals were subsequently challenged by injection of 40 µl (1 mg/mL) of Candida
albicans chitosan antigen in the right footpad. Twenty-four hours later, the thickness of the right
footpad was measured. The mean change in footpad thickness was calculated for each mouse
(post-challenge minus pre-challenge thickness) and data expressed as footpad swelling in mm x
100.

Flow Cytometric Analysis
The percentages and total number of lymphocyte subsets in the spleen were measured
using flow cytometry [Guo et al. 2001]. All antibodies used were obtained from BD Pharmingen
(San Diego, CA., USA) and diluted 1:80 with staining buffer which include rat anti-mouse CD4–
PE, anti-mouse CD8a–FITC, anti-mouse CD3– FITC, anti-mouse CD25–FITC, anti-mouse
NK1.1-PE, and anti-mouse Mac3-FITC. Isotype-matched irrelevant antibodies were used as
controls. Spleen single-cell suspensions (1 x106 cells/well) were dually labeled with 100 µL
fluorescein isothiocyanate (FITC)-conjugated and phycoerythrin (PE)-conjugated antibodies in
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the presence of anti-CD16/32 (Mouse FC block) for 30 min on ice. Following initial staining
with antibody and washing with staining buffer, propidium iodide (PI, 100 µL of 0.005 mg/mL,
Sigma-Aldrich) solution was added as a non-viable cell label. A Becton Dickinson FACScan®
Flow Cytometer was used for enumeration where log fluorescence intensity is read gated on PI
to eliminate dead cells and a forward scatter threshold high enough to eliminate red blood cells.
Data were analyzed using CellQuestTM software (Becton Dickinson, San Jose, CA).

Statistical Analysis
All results were evaluated in JMP® software using a parametric one-way analysis of
variance (ANOVA), and Dunnett’s Test was used to compare differences between the treatment
and sham control groups. Additional control groups, including naïve and positive controls, were
tested using a separate ANOVA and compared with the sham control using the Dunnett’s t-Test.

Results and Discussion
Effect of EPCL on Splenocyte Phenotype
As shown in Table 3, following analysis by flow cytometry, microfibrous EPCL did not
affect absolute number or percentage of T cells, T cell subsets, macrophages or natural killer
cells at any dose level. The percentage of B cells was slightly increased with 1 implant (5%
increase), however, the absolute number of B cells was not affected. The slight increase in
percentage of B cells only occurring only at the low dose is not likely to be treatment-related and
is not believed to be biologically relevant.
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As seen in Table 4, nanofibrous EPCL did not affect the absolute number or percentage
of B cells, T cells, T cell subsets, or natural killer cells at any dose level. The percentage and
absolute number of macrophages was decreased with 1, 2, and 4 nanofibrous implants when
compared to sham control. However, these decreases were not dose-responsive and do not
appear to be treatment-related.

71
Table 3. Splenocyte subsets following microfibrous EPCL implantation. Results are presented as mean ± S.E. for absolute or
percent cells. The level of statistical significance is denoted as ** p < 0.01 or * p < 0.05 as compared to the sham control group. N/C =
not conducted. Only appropriate controls were used for each cell type.

!
!
!
!
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Table 4.!Splenocyte subsets following nanofibrous EPCL implantation. Results are presented as mean ± S.E. for absolute or
percent cells. The level of statistical significance is denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group. N/C =
not conducted. Only appropriate controls were used for each cell type.

Effect of EPCL on Innate Immunity: NK Cytotoxicity
Results of natural killer cell percent cytotoxicity are shown in Figure 8. Neither
microfibrous nor nanofibrous EPCL had effects on natural killer cell activity in 24-28
week old female B6C3F1 mice. The positive control animals, which received AAGM1,
had minimal cytotoxic activity.

73

Figure 8.!Natural Killer cell activity. Results are presented as mean ± S.E. for percent cytotoxicity. Anti-asialo GM1
(AAGM1) was administered to positive control animals by i.v. injection on day 28. The level of statistical significance is
denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group.
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Effect of EPCL on Humoral Immunity: AFC and sRBC ELISA
AFC assay results are presented in Figure 9 and 10 as AFC/106 spleen cells
(specific activity) and total spleen activity. Microfibrous EPCL did not significantly affect
the AFC response to sheep erythrocytes when evaluated as either specific activity or as
total spleen activity in 24-28 week old female B6C3F1 mice (Figure 9). Animals exposed
to nanofibrous EPCL did demonstrate a statistically significant decrease in total activity at
the middle dose, and a slight, albeit not statistically significant, decrease can be observed at
each dose level. Results were obtained from combining two studies, each of which utilized
seven or eight animals per group. CPS significantly suppressed the AFC response as
expected.
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Figure 9.!Spleen IgM Antibody-Forming Cell (AFC) Response to Sheep Erythrocytes. Female B6C3F1 mice were exposed
to microfibrous of nanofibrous EPCL for 28 days and were immunized with sRBCs on day 25. Results are presented as
percent control mean ± S.E. for the AFC/106 Spleen Cells (specific activity) and AFC/Spleen (total spleen activity). On days
25-28, 50 mg/kg cyclophosphamide (CPS) was administered as a positive control by i.p. injection. The level of statistical
significance is denoted as ** p < 0.01 as compared to the sham control group.
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Figure 10.!Spleen IgM Antibody-Forming Cell (AFC) Response to Sheep Erythrocytes. Female B6C3F1 mice were exposed
to microfibrous of nanofibrous EPCL for 28 days and were immunized with sRBCs on day 25. Results are presented as
percent control mean ± S.E. for the AFC/106 Spleen Cells (specific activity) and AFC/Spleen (total spleen activity). On days
25-28, 50 mg/kg cyclophosphamide (CPS) was administered as a positive control by i.p. injection. The level of statistical
significance is denoted as ** p < 0.01 as compared to the sham control group.
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Shown in Figure 11 are sRBC ELISA results, expressed as mean Log2(Titer).
Neither microfibrous or nanofibrous EPCL produced any significant effects compared to
the sham control. Positive control mice, which received CPS, had a significant decrease in
the serum IgM response to sRBC compared to the sham control.
Taken with results from the sRBC ELISA, other measures of immune function, and
lack of a dose-responsive trend with nanofibrous EPCL in the AFC assay it is not believed
to be toxic to humoral immunity in aged animals.
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Figure 11. sRBC ELISA. Results are presented as Titer (Log2) Mean ± S.E.. Level of statistical significance is denoted as **
p < 0.01 as compared to the sham control group.
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Effect of EPCL on Cell-mediated Immunity: DTH
Results of the DTH response are shown in Figure 12 and presented as footpad
swelling in mm x 100. Surgical implantation of microfibrous or nanofibrous EPCL did not
affect the DTH response to C. albicans in 24-28 week old female B6C3F1 mice. The
positive control group, which received CPS, had significantly decreased footpad swelling
when compared to the sham control. Additionally, footpad swelling of the challenge only
group was significantly less than the sham control group, which had received both
sensitization and challenge.
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Figure 12. Delayed type hypersensitivity response to C. albicans. Results are presented as Mean ± S.E. footpad swelling
(mm*100). Level of statistical significance is denoted as ** p < 0.01 as compared to the sham control group.
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Conclusions
The work was undertaken to examine aged animal immune responses to EPCL due
to the potential use in applications intended for an aged patient population. Overall, results
from innate, cell-mediated, and humoral immune tests demonstrate microfibrous and
nanofibrous EPCL do not affect immune responses in aged animals. Therefore, studies
indicate that EPCL is a material with excellent immunocompatibility deserving further
investigation for tissue engineering applications including those for elderly populations.
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CHAPTER 5: Additional Studies of Lidocaine and EPCL
Lidocaine
A topical analgesic was required following survival surgery by the VCU IACUC. A
preliminary study was permitted to test the chosen analgesic. Analgesics, which can
include opiods, non-steroidal anti-inflammatory drugs, and local analgesics, can interfere
with the immune system [Piersma et al. 1999]. Due to the immunodulatory potential of
these medications they are typically not used in immunology research [Piersma et al.
1999]. Lidocaine was found to have the least documented immunomodulatory effects of
the considered analgesics. A study by Dickstein et al. showed effects on lymphocyte
proliferation assays when mice were exposed to 0.25 mg/10 g body weight lidocaine by
i.p. injection four times a day for 7 days [Dickstein et al. 1985]. In the presented studies,
animals were exposed to a small dab of lidocaine on each incision site once a day for three
days. In order to determine if the lidocaine would interfere with the studies, a study was
conducted where animals were exposed to lidocaine for three days and on day 15 of the
study the antibody forming cell assay was conducted. Three groups were used, a naïve
group (NA) which received no treatment, a sham surgery group (SH) which received the
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same sham surgery as conducted in the EPCL studies without lidocaine, and a lidocaine
(LDC) group which received sham surgery and three days of lidocaine treatment. As
shown in Figure 13, the lidocaine treatment did not affect the AFC response.

Figure 13. Antibody forming cell response following surgical treatment and lidocaine exposure. Groups tested were naïve
(NA), sham control without lidocaine (SH) and sham control with lidocaine treatment for 3 days (LDC).
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Additional EPCL Studies
Additional endpoints were evaluated but not pursued for all combinations of fiber
size and age. Endpoints included were B-cell and T-cell lymphocyte proliferation assays.

Methods
The lymphocyte proliferation assays anti-CD3, concanavlin A (con A), and
lipopolysaccharide (LPS), and the mixed leukocyte response (MLR), were conducted on
young animals following exposure to microfibrous EPCL. Assays were conducted on day
29 and have been described previously by Guo et al. [Guo et al. 2001].

Anti-CD3 Antibody Mediated T-cell Proliferation
On day 29 animals were humanely euthanized and splenocytes were prepared and
diluted in EBSS to 2 x106 cells/mL. 96-well BioCoat T-Cell activation plates were used, to
stimulate T-cell proliferation anti-CD3 antibody coated plates were used and for controls
uncoated control plates were used (BD Biosciences, San Jose, CA). 200 µl of splenocytes
and 100 µl of RPMI were added to both the stimulated and unstimulated wells (4 replicates
per animal) and plates were incubated for 3 days at 37°C with 5% CO2 and 95% humidity.
On day 2 of incubation, the cells were pulsed with 3H-thymidine (50 µCi/mL, 20 µl/well).
On day 3 of incubation, 18-24 hours after pulsing, cells were harvested using a Tomtec
Harvester 96 Mach IIM (Tomtec, Hamden, CT) onto Wallac filtermats (Wallac, Turku,
Finland), and scintillation fluid was added and the filtermats were counted on a 1450
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Microbeta Trilux liquid scintillation and luminescence counter (Perkin Elmer,
Gaithersburg, MD). The incorporation of 3H-thymidine into the proliferating cells was
used as the endpoint of the assay, and the data expressed as counts per minute
(CPM)/2x105 cells.

Concanavalin A Stimulated T-Cell Proliferation
The con A assay was performed similarly to the anti-CD3, splenocytes were added
at 2x106 cells/well to wells with con A (Amersham Pharmacia, Bjorkgatan, Sweden) at
four dilutions 10, 5, 2.5, or 1.25µg/mL (with 3 replicate wells for each concentration and 3
for unstimulated controls) and plates were incubated, pulsed and harvested in the manner
as anti-CD3. The endpoint for the con A assay was also incorporation of 3H-thymidine into
the proliferating cells and expressed as cpm/2x106 cells.

F(ab’)2 + IL-4 Stimulated B-Cell Proliferation
The F(ab’)2 + IL-4 assay was performed similarly to the anto-CD3, splenocytes
were added at 2x106 cells/well to wells with media only, or F(ab’)2 antibody fragment
only, (Accurate Chemical, Westbury, NY) or F(ab’)2 with 10 ng/mL IL-4 (R&D Systems,
Minneapolis, MN) and plates were incubated, pulsed and harvested in the manner as antiCD3. The endpoint for the con A assay was also incorporation of 3H-thymidine into the
proliferating cells and expressed as cpm/2x106 cells.
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Lipopolysaccharide Stimulated B-cell Proliferation
In the LPS assay splenocytes were added at 2x105 cells/well to wells with 100
µg/mL LPS derived from Salmonella typhosa (Sigma Aldrich, St. Louis, MO) (with 4
replicate wells for stimulated and 4 wells for unstimulated controls) and plates were
incubated, pulsed and harvested in the manner as anti-CD3. The endpoint for the LPS
assay was also incorporation of 3H-thymidine into the proliferating cells and expressed as
cpm/2x105 cells.

The Mixed Leukocyte Response
The one-way mixed leukocyte response to DBA/2 spleen cells measures the
proliferation of T cells in response to an allogeneic stimulus (the DBA/2 mouse spleen
cells) [Guo et al. 2001]. On day 29, animals were humanely euthanized and splenocytes
from exposed mice (responders) were prepared, diluted and added to U-bottom 96-well
plates at a concentration of 1x105 cells/well. The allogeneic (stimulator) cells from DBA/2
mice were treated with mitomycin C (0.5mg/2x108 cells) (Sigma Aldrich, St. Louis, MO)
for 45 minutes at 5% CO2 and 37°C to stop proliferation. The stimulator cells were then
washed four times with EBSS and diluted in RPMI at a concentration of 4x106cells/mL.
Each plate row contains 4 wells of unstimulated responder cells with RPMI and 4 wells of
responder plus stimulator cells. The cells were co-cultured for 5 days with 5% CO2 and
37°C. On day 4 of incubation the cells were pulsed with 3H-thymidine (50µCi/mL, 20
µl/well). On day 5 of incubation, 18-24 hours after pulsing, cells were harvested using a
Tomtec Harvester 96 Mach IIM (Tomtec, Hamden, CT) onto Wallac filtermats (Wallac,
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Turku, Finland), and scintillation fluid was added and the filtermats were counted on a
1450 Microbeta Trilux liquid scintillation and luminescence counter (Perkin Elmer,
Gaithersburg, MD). The incorporation of 3H-thymidine into the proliferating cells was
used as the endpoint of the assay, and the data expressed as cpm/1x105 cells.

Positive Control
For all lymphocyte proliferation assays CPS was used as the positive control
administered at 50 mg/kg by i.p. injection on days 25-28.

Results

Anti-CD3 Antibody Mediated T-cell Proliferation
As shown in Figure 14, two studies were conducted in young animals following
exposure to microfibrous EPCL using the anti-CD3 antibody mediated T-cell proliferation
assay. In the first study, naïve and sham controls and EPCL treated groups were not
different. In the second study, the sham control was significantly lower than the naïve
response and the 2-implant group was significantly increased above the sham control. In
both studies, the positive control significantly suppressed the response.

Figure 14. Proliferation response to anti-CD3. Results are presented as mean ± S.E.. The level of statistical significance is
denoted as ** p < 0.01 or *p < 0.05 as compared to the sham control group.
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Mixed Leukocyte Response
As shown in Figure 15, two studies were conducted in young animals following
exposure to microfibrous EPCL using the mixed leukocyte response. In the first study,
naïve and sham controls and EPCL treated groups were not different. In the second study,
the sham control was significantly lower than the naïve response and the 1-implant and 2implant groups were significantly increased above the sham control. In both studies, the
positive control significantly suppressed the response.

91

Figure 15. Mixed leukocyte response. Results are presented as mean ± S.E. The level of statistical significance is denoted as
**p < 0.01 or *p < 0.05 as compared to the sham control group.
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Concanavalin A Mediated T-cell Proliferation
As shown in Figure 16, one study was conducted in young animals following
exposure to microfibrous EPCL using the concanavalin A mediated t-cell proliferation
assay. In the study, naïve and sham controls and EPCL treated groups were not different.
The positive control significantly suppressed the response.

Figure 16. Concanavalin A stimulated proliferation. Results are presented as mean ± S.E.
The level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to
the sham control group.
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F(ab’)2 + IL-4 Stimulated B-Cell Proliferation
As shown in Figure 17, one study was conducted in young animals following
exposure to microfibrous EPCL using the F(ab’)2 + IL-4 stimulated B-cell proliferation
assay. In the study, the naïve control was significantly higher than the sham control. The 2implant EPCL group was significantly lower than the sham control and the positive control
significantly suppressed the response.

Figure 17. F(ab’)2 + IL-4 simulated proliferation. Results are presented as mean ± S.E. The
level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the
sham control group.
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Lipopolysaccharide Stimulated B-Cell Proliferation
As shown in Figure 18, one study was conducted in young animals following
exposure to microfibrous EPCL using the lipopolysaccharide stimulated B-cell
proliferation assay. In the study, the naïve control was significantly higher than the sham
control. The EPCL groups were not significantly different than the sham control and the
positive control significantly suppressed the response.

Figure 18. Lipopolysaccharide stimulated proliferation. Results are presented as mean ±
S.E. The level of statistical significance is denoted as ** p < 0.01 or *p < 0.05 as compared
to the sham control group.
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Discussion
The lymphocyte proliferation assays are used to measure T-cell and B-cell
proliferation by ex vivo stimulation. Normal physiological T-cell stimulation occurs
through antigen-specific binding to the T-cell receptor. CD3 is a pan T-cell marker and Tcell receptor subunit that can activate T-cell proliferation with appropriate co-stimulation
(provided in the spleen suspension by antigen-presenting cells) [Pitcher et al. 2005,
Janeway 2008]. Mitogens such as con A are capable of causing polyclonal lymphocyte
proliferation, con A specifically stimulates T-cells [Janeway 2008]. In the mixed leukocyte
response, responder T-cells proliferate in response to “non-self" allogeneic T-cells, the
DBA/1 stimulator cells. Lipopolysaccharide is a mitogen, which stimulates polyclonal B
cell proliferation [Janeway 2008]. F(ab’)2 stimulates the B-cell receptor (IgM antibody
immobilized on the B-cell surface), however alone cannot stimulate antibody production,
the addition of IL-4 can provide the necessary signal for cross-linking and B-cell
proliferation [Parker et al. 1980].
Results from these studies were inconsistent. In the first anti-CD3 study no
differences were observed between sham and EPCL-treated groups, with the EPCL-treated
groups having slightly lower means than the sham control. In the second anti-CD3 study,
the sham control response was lower than the naïve response and EPCL-treated groups
were higher and more similar to the naïve response with the 2-implant group significantly
higher than the sham. Taken together it is unlikely that these results are biologically
significant. Similar results were obtained in the MLR studies; in the second MLR study
both the 1-implant and 2-implant groups were significantly higher than the sham control.
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In the third T-cell proliferation assay, con A, no differences were observed between naïve,
sham, or EPCL-treated groups. Considering consistent results of no effect in the holistic
assay the delayed-type hypersensitivity response to C. albicans, which requires T-cell
proliferation, the overall evidence suggests that T-cell responses are not affected by EPCL.
The B-cell proliferation assays also resulted in non-dose responsive results. In the
F(ab2)’ + IL-4 assay, the naïve group was significantly higher than the sham control group,
and of the EPCL-treated groups a significantly lower response was seen in the 2-implant
group. In the LPS assay, a significantly higher response was seen in the naïve group over
the sham control while no differences were seen between the sham and EPCL-treated
groups. General trends in these studies were opposite, where 2-implant and 4-implant
EPCL-treated groups in the F(ab2)’ + IL-4 study were lowest, in the LPS study the 2implant and 4-implant groups had higher means than the sham and 1-implant groups.
Taken with consistent results of no effect in young animals in the holistic AFC assay,
which requires antibody production, the overall evidence suggests that B-cell responses are
not affected by EPCL.
The lymphocyte proliferation studies were conducted only with the young animals
and microfibrous EPCL given the overall weight of evidence that EPCL does not cause
immunotoxicity in the holistic assays requiring lymphocyte function. Additionally, SigmaAldrich stop producing the original lot of PCL, remaining PCL from the original lot was
used to complete aged animal studies.
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New PCL Lot
Due the discontinuation of the original lot of PCL (molecular weight 65,000 kDa),
the concentration of 50 mg/mL for nanofibrous scaffolds was established for the new lot
(molecular weight 70,000-90,000 kDa) as shown in Figure 19. Mean fiber diameter was
determined to be 0.56 ± 0.03 µm. As seen in Figure 20, the second lot of PCL did not
affect the c. Albicans DTH.

Figure 19. Scanning electron micrograph of nanofibrous EPCL with the second lot of PCL.

Figure 20. Results of c. Albicans DTH following exposure to the second lot of EPCL.
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CHAPTER 6: Determination of Systemic Dexamethasone
Effects
Introduction
Dexamethasone (DEX) is a known immunosuppressive agent, which has been
studied, in rodent models. Studies by Munson et al. and White et al. in mice have
demonstrated that DEX is suppressive in the DTH to sRBC and c. Albicans, respectively
[Munson et al. 1982, White et al. 2012]. In order to determine endpoints to be evaluated in
studies with dexamethasone-loaded EPCL (DEX-EPCL) various endpoints were evaluated
following subcutaneous injection of dexamethasone. The endpoints evaluated included,
body and organ weights, the antibody forming cell assay, hematology parameters, bone
marrow cell counts, and the delayed-type hypersensitivity response.

Methods
Mice were treated with vehicle (4.75% ETOH in PBS) or Dexamethasone (0.01,
0.03, 0.1, or 0.3 mg/kg) by subcutaneous injection daily for 8 days. The positive control,
cyclophosphamide (CPS), was administered i.p. on days 5-8.
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The body and organ weights, and delayed-type hypersensitivity response were
conducted as previously described in Chapters 1 and 2.
Bone marrow counts were obtained by removing femurs, resecting skin and
muscle, and cutting without breaking the bone at both joints. The bones were placed in
15mL conical tubes with MEM medium (GibcoBRL, Grand Island, NY, USA) until
flushing. To flush the femurs, a 23G needle was used to puncture the distal end of the
femur and the marrow plug was flushed with 2.5 mL of MEM medium. Cells were
centrifuged at 1200 ± 100 rpm (300 ± 10 x g) for approximately 10 minutes at 2-8°C and
cells were resuspended in 1mL of MEM medium. Cells were counted with a ZBII
Coulter® counter.
For hematology analysis, on the day of sacrifice, animals were anesthetized with
CO2 and blood was collected from the retro-orbital sinus into EDTA tubes. Total numbers
of leukocytes, leukocyte differentials, erythrocyte number, hemoglobin concentration,
hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC), and platelet number were
determined using a Hemavet® hematology analyzer.
Results and Discussion
Spleen and Thymus Weights
The spleen and thymus weights of animals exposed to dexamethasone by s.c.
injection at all dose levels were significantly decreased compared to vehicle control as
shown in Figure 21. The positive control group, 4 days of 50 mg/kg cyclophosphamide

102
also significantly suppressed both spleen and thymus weights. These results indicate that
spleen and thymus weights would be sensitive endpoints for detecting systemic
immunosuppression from DEX and were chosen as endpoints for DEX-EPCL studies.

Figure 21. Spleen and thymus weights mice were treated with vehicle (4.75% ETOH in PBS) or dexamethasone by
subcutaneous injection daily for 8 days. The positive control, cyclophosphamide (CPS), was administered i.p. on days 5-8.
Results are presented as mean ± S.E. The level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to
the vehicle control group.
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Delayed-Type Hypersensitivity Response
Following exposure to dexamethasone by s.c. injection the lowest dose (0.01
mg/kg) did not have significantly decreased swelling the DTH response to C. albicans. A
dose-responsive decreasing trend was seen and all remaining doses significantly decreased
footpad swelling. The positive control group, 4 days of 50 mg/kg cyclophosphamide also
suppressed the response and the challenge-only group had minimum swelling, both groups
were significantly different from the vehicle control. These results indicated that the c.
Albicans DTH model would be an appropriate model for use in the DEX-EPCL studies.

Figure 22. Delayed-type hypersensitivity response to C. albicans. Results are presented as
mean ± S.E. for footpad swelling (mm*100). The level of statistical significance is denoted
as **p < 0.01 or *p < 0.05 as compared to the sham control group.
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Bone Marrow Cellularity
Bone marrow cellularity was not decreased from vehicle control at any dose tested
following 8 days of dexamethasone exposure by s.c. injection. Therefore, bone marrow
cellularity was not used in evaluating DEX-EPCL. The positive control group, 4 days of 50
mg/kg cyclophosphamide significantly suppressed bone marrow cell number.

Figure 23. Bone marrow cellularity. Results are presented as mean ± S.E. for bone marrow
cell number. The level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as
compared to the sham control group.
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Hematology Parameters
The results of hematology parameters of animals exposed to dexamethasone by s.c.
are shown in Table 5. MCV was the only parameter affected at all dose levels. Percent
lymphocytes and total red blood cells (RBC) were increased at the highest dose. HCT was
slightly decreased at the lowest dose. Since changes in hematology parameters were
relatively small and changes for all dose levels was only observed for one parameter
hematology was not used as an endpoint in DEX-EPCL studies.

Table 5. Hematology parameters. Results are presented as mean ± S.E. The level of statistical significance is denoted
as **p < 0.01 or *p < 0.05 as compared to the sham control group.
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CHAPTER 7: Studies on Dexamethasone-loaded EPCL
Scaffolds
Introduction
According to the Center for Disease Control (CDC), in 2007-2009 50% of adults
age 65 or older and 22% of all adults had been diagnosed with arthritis. The most common
form is osteoarthritis, however rheumatoid arthritis and other conditions (gout,
fibromyalgia) are also highly prevalent [CDC 2010]. Arthritis leads to joint inflammation
and degradation, which can lead to the need for total joint replacement in order to maintain
ability to conduct vital activities such as walking and bending [CDC 2010]. Current
treatments for arthritis include oral, (i.e. systemic) administration with methotrexate,
glucocorticoids, and/or biologicals. Due to systemic administration, all of these treatments
have potential systemic immunomodulatory effects, which can lead to increased
susceptibility to infection [Klarenbeek et al. 2010].
This work was undertaken to explore a novel drug delivery system to locally
deliver immunomodulators to inflamed joints while aiming to reduce or eliminate systemic
effects. The polymer studied, electrospun polycaprolactone (EPCL), was chosen because it
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is biodegradable and previous studies have shown it is immunocompatible [McLoughlin et
al. 2012]. Having demonstrated that EPCL alone does not adversely effect any of the
immune components evaluated, including the delayed-type hypersensitivity (DTH)
response we chose to study EPCL loaded with the known immunosuppressive compound,
dexamethasone, as a potential drug delivery system.
Dexamethasone has been incorporated into various non-electrospun materials and
devices for local anti-inflammatory activity and drug delivery. Silva-Cunha et al.
incorporated dexamethasone into PCL through lyophilization and compression into discs
for intravitreous devices and found that these were well-tolerated in rabbit eyes with
prolonged drug release [Silva-Cunha et al. 2009]. Ward et al. examined dexamethasone
with low release in pigs with subcutaneously implanted biosensors and found that
decreases in local inflammatory responses were possible without systemic effects [Ward et
al. 2009]. Pital et al. combined dexamethasone with vascular endothelial growth factor
(VEGF) in PLGA microsphere/PVA hydrogel composites and along with decreasing local
inflammation were able to promote neo-angiogenesis otherwise inhibited by
dexamethasone [Pital et al. 2007].
Electrospun polymers, including EPCL have been studied as drug delivery systems
for a range of compounds including antibiotics, growth factors, and nucleic acids.
Techniques for drug loading of electrospun polymers include: post-electrospinning
modification (drug absorption or covalent coupling to the scaffold following
electrospinning), direct electrospinning of a drug/polymer solution, coaxial electrospinning
of a core containing drug/polymer and polymer shell. Each technique has unique benefits,

110
the method chosen here was direct polymer/drug electrospinning, which tends to lower
burst release compared to post-electrospinning modification [Meinel et al. 2012]. Kenawy
et al. studied the release of tetracycline hydrochloride from two polymers individually,
poly(ethylene-co-vinylacetate) (PVA) and poly(lactic acid) (PLA) and from a 50:50 blend
of the two. Release profiles were characterized using UV-VIS and results indicated that
release was sustained over approximately 5 days [Kenawy et al. 2002]. Sell et al. examined
the release of platelet-rich plasma (PRP) from silk fibroin (SF), PGA, and PCL electrospun
scaffolds and found that protein release occurred for up to 35 days in vitro and enhanced
scaffold bioactivity [Sell et al. 2011]. Martins et al. electrospun DEX with PCL to promote
osteogenic differentiation of human bone marrow-derived stem cells (hBMSCs) and found
that the drug had sustained release for over 15 days and promoted an osteoblastic
phenotype [Martins et al. 2010].
In the present work, three models were used to examine the ability of DEX-EPCL
scaffolds to reduce local inflammatory effects and determine systemic immunomodulatory
effects. The delayed-type hypersensitivity response to C. albicans, keyhole limpet
hemocyanin induced footpad swelling, and a collagen-induced arthritis model. Local
effects were assessed by measuring footpad swelling and spleen and thymus weights were
measured as systemic endpoints.
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Materials and Methods
Scaffold Preparation and Animal Husbandry
Electrospinning was conducted as described previously, however due to change in
polycaprolactone (PCL, molecular weight 70,000-90,000 kDa Sigma-Aldrich) lot and
molecular weight the PCL concentration used was 50 mg/mL. Dexamethasone (DEX,
Sigma-Aldrich) was added to the polymer solution approximately 20 minutes before
electrospinning at 3, 10, 30, or 100% w/w. Materials were disinfected by overnight
exposure to UV light in a biological safety cabinet. Preliminary studies were conducted by
implanting animals with 6-mm or 3-mm disks of DEX-EPCL obtained using biopsy
punches (Fisher Scientific). Animal husbandry was conducted as previously described in
Chapters 1 and 2. The DEX-EPCL was implanted as close to the inflamed joint as possible.

Delayed-Type Hypersensitivity Studies
In the DEX-EPCL studies with the DTH model, animals were sensitized and 24
hours later implanted. Eight days later, footpads were pre-measured and all animals were
challenged. The pilot study was conducted with 6-mm implants containing 65, 100, or
200% DEX-EPCL and 4 animals per group. Subsequently, studies were conducted with 3,
10, 30, and 100% DEX-EPCL and 6-mm or 3-mm disks with eight animals per group. In
order to compare between studies DEX-Equivalent Units were established, as shown in
Figure 24, by multiplying the concentration of DEX by surface area of the implant. Spleen
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and thymus weights were obtained for all studies. The positive control used in the DTH
studies was 50 mg/kg CPS given the last four days.

Figure 24. DEX-equivalent units.

Keyhole Limpet Hemocyanin Studies
Mice were implanted with DEX-EPCL approximately 24 hours after KLH injection
(200 µg/mouse) in the right footpad. Two studies were conducted, in the first study footpad
measurements were taken on days 1, 2, 4, and 7 after surgery and in the second study on
days 1, 2, 3 and 4. Spleen and thymus weights were obtained only for the second study.
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The positive control used in the studies was dexamethasone given by s.c. injection. In the
first study, a single injection of 0.5 mg/kg was given the same day as surgeries were
conducted, which was insufficient to reduce footpad swelling. The positive control was
given again on days 4 and 6 of the study (3 and 5 days after implantation). In the second
study, the dose was increased to 1mg/kg and given on both the day of and the day after
surgery.

Collagen-Induced Arthritis Studies
Arthritis was induced as described by Bevaart. Mice were first injected at the base
of the tail with 100 µl of an emulsion of chicken collagen type II (Chondrex, Inc.
Redmond, WA) and complete freund’s adjuvant (CFA, Chondrex, Inc. Redmond, WA). A
booster injection of collagen and incomplete freund’s adjuvant (IFA, Chondrex, Inc.
Redmond, WA) was given 3 weeks later [Bevaart et al. 2010]. A preliminary study was
conducted to establish the time course in the B6C3F1 mouse. A second study was
conducted for DEX-EPCL exposure. The positive control used in the DEX-EPCL study
was 1 mg/kg DEX given by s.c. injection given on days before measurement.

Results
Delayed-Type Hypersensitivity Study 1
As shown in Figure 25, a decreasing trend was seen in the spleen weights of the 3
DEX-EPCL groups with a significant decrease at the highest dose, thymus were unaffected
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and the positive control group was significantly decreased in both spleen and thymus
weights.
There was a decreasing trend with all DEX-EPCL groups in the DTH response to
C. albicans as shown in Figure 26 with a significant decrease at the highest dose.

Figure 25. Spleen and Thymus weights. Results are presented as mean ± S.E. The level of statistical significance is denoted
as ** p < 0.01 or *p < 0.05 as compared to the sham control group.
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Figure 26. Delayed-type hypersensitivity response to C. albicans. Results are presented as
mean ± S.E. The level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as
compared to the sham control group.
Delayed-Type Hypersensitivity Studies 2 and 3
In Figures 27-29 the results from DEX-EPCL studies 2 and 3 are shown according
to DEUs and presented in percent control. The lowest dose, 21 DEU did not result in
decreases in footpad swelling, thymus weight, or spleen weight. The next 3 higher doses,
70, 84, and 210 DEU resulted in a decrease in footpad swelling without decreases in spleen
or thymus weight. The groups 280. 700, and 840 DEU resulted in decreases in footpad
swelling and decreases in thymus weight. The highest dose, 2800 DEU resulted in
decreases in footpad swelling, spleen, and thymus weight. Based on these results the 3-mm
implants were chosen for further study.
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Figure 27. DEX-EPCL Studies 2 and 3. Footpad swelling. Results are presented as % control mean ± S.E. The level of
statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.
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Figure 28. DEX-EPCL Studies 2 and 3. Spleen weight. Results are presented as percent mean ± S.E. The level of statistical
significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.
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Figure 29. DEX-EPCL Studies 2 and 3. Thymus weight. Results are presented as percent control mean ± S.E. The level of
statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.

Keyhole Limpet Hemocyanin Studies
KLH study 1, shown in Figure 30 (top panel), showed little difference between
DEX-EPCL treated groups and the material-only (MO) control in days 1, 3, or 6 days after
implantation (which occurred on day 1 in the graphs). At day 3 the high dose, 700 DEU
had significantly reduced footpad swelling compared to control. On day 6 after
implantation the two highest doses, 210 and 700 DEU had significantly reduced footpad
swelling from material only control, however the MO response by day 6 had decreased to
less than half the peak response. The positive control was decreased.
KLH study 2, shown in Figure 30 (bottom panel), showed similar results to KLH
study 1. The naïve control was significantly less than the material only control on the day
of implantation (day 1 in the graphs). On day 2 after implantation the high dose, 700 DEU,
had significantly decreased footpad swelling and on day 3 after implantation 3 of the DEXEPCL groups 70, 210, and 700 had significantly decreased footpad swelling compared to
the material control. The peak response in study 2 was much lower then in study 1 and by
day 3 after implantation the MO response was similar to study 1 at day 7. The spleen and
thymus weights were significantly decreased at the end of study by the high doses of DEXEPCL (210 and 700 DEU) and by the positive control.
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Figure 30. KLH Studies 1 (top panel) and 2 (bottom panel) results of footpad swelling (mm*100). Results are presented as
mean ± S.E. The level of statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the sham control group.
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Figure 31. KLH Study 2. Spleen and Thymus weights. Results are presented as mean ± S.E. The level of statistical
significance is denoted as **p < 0.01 or *p < 0.05 as compared to the sham control group.
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Collagen-Induced Arthritis Study 1
A pilot study of the collagen-induced arthritis model was conducted in the B6C3F1
mouse in order to determine feasibility and time course compared to the prototypic strain
used in the model, the DBA/1. 78 B6C3F1 mice were used and 18 (23% incidence)
developed inflammation in at least one paw starting at approximately 2-3 weeks after the
second injection. Consistent with the DBA/1 model swelling persisted over an additional
3-4 weeks.

Collagen-Induced Arthritis DEX-EPCL Study
In the CIA DEX-EPCL, study animals that developed arthritis in at least one paw
were implanted 4 weeks after the second injection. In the study, 106 B6C1F3 mice were
injected and 27 developed arthritis (25% incidence). Animals were randomized and
distributed throughout the groups, the 84 DEU group had 3 animals while all other groups
had n = 4. As seen in Figure 32, body and thymus weights were unaffected for all groups.
Spleen weights were significantly decreased for the positive control, 21, 210, and 700
DEU groups. Footpad measurements were obtained on days 3, 4, 5, 11, 12, 13, 14, 18, and
20 after implantation as seen in Figures 33-35. No significant differences were found in
change in footpad swelling between measurement days and the day of implantation as
compared to the material only group. Starting on day 13 most groups tended to have an
increase in footpad swelling over the day of implantation.
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Figure 32. CIA Study 2 Body, Spleen, and Thymus weights. Results are presented as mean ± S.E. The level of statistical
significance is denoted as **p < 0.01 or *p < 0.05 as compared to the sham control group.
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Figure 33 CIA DEX-EPCL Study Footpad swelling Days 3, 4, and 5. Results are presented as mean ± S.E. The level of
statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.
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Figure 34. CIA DEX-EPCL Study Footpad swelling Days 11, 12, and 13. Results are presented as mean ± S.E. The level of
statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.
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Figure 35. CIA DEX-EPCL Study Footpad swelling Days 14, 18, and 20. Results are presented as mean ± S.E. The level of
statistical significance is denoted as **p < 0.01 or *p < 0.05 as compared to the material only control group.

Discussion
Dexamethasone is a potent glucocorticoid. Glucocorticoids are used to treat
autoimmune and inflammatory diseases and act on components of both the adaptive and
innate immune response. Glucocorticoids decrease inflammation by enhancing
opsonization and scavenger system activity and therefore enhancing clearance of antigens,
toxins, dead cells, and microorganisms. Additionally, glucocorticoids downregulate
cytokines (IL-1β, TNFα, IL-6, IL-8, IL-12, and IL-18) and chemokine release while
promoting anti-inflammatory cytokines (IL-10 and TGFβ) and receptors for proinflammatory cytokines. In T-cell dependent responses, glucocorticoids promote a humoral
Th2 immune response over a cell-mediated Th1 immune response by blocking IL-12
production by monocytes and dendritic cells and enhancing IL-10 secretion by
macrophages. Glucocorticoids have varied effects on T-cell survival and apoptosis that are
dependent on the T-cell type, activation state, and relative time of exposure to activation.
The outcome may be due to whether signaling occurs through the T-cell receptor alone,
glucocortoid receptor alone, or during concominant signaling [Franchimont 2004].
The delayed-type hypersensitivity response to c. albicans has been shown to
primarily involve cell-mediated immunity with no major involvement of humoral
immunity [Smith and White 2010]. Result from the DEX-EPCL studies indicated that the
drug delivery system was able to successfully significantly decreases footpad swelling in
the model which is likely due to a primarily Th1 response. The model was likely the most
successful because the implants were present prior to challenge priming the immune
system towards a Th2 over a Th1 response. A dose (70 DEU) was found that was able to
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successfully decrease footpad swelling without effects on spleen or thymus weights. From
these results the 3-mm implants were chosen for further study.
The keyhole limpet hemocyanin model is likely an inflammatory response caused
by an influx of neutrophils and macrophages [Engstrom et al. 2009]. In the second KLH
study, a similar successful response was seen with the 70 DEU group on day 3 after
implantation where footpad swelling was decreased without effects on spleen or thymus
weights. Variability in the model itself (responses between studies, and inconsistency
between controls in study 2) and relatively fast waning phase decrease the usefulness in
evaluating the DEX-EPCL system.
The collagen-induced arthritis model and genetic and immunological processes in
mice with the H-2q susceptible haplotype, including the prototypic strain the DBA/1, are
well characterized. The likely mechanism of induction of arthritis starts with a T-cell
response, promoted my mycobacteria components of the CFA, occurring in the draining
lymph nodes at the site of collagen/IFA challenge. Naïve T-cells are then promoted to
differentiate into Th1 cells which promotes isotype switching and production of IgG2a by
collagen-specific B-cells. Antibodies enter the joint and bind collagen, which activates
complement in turn activating blood vessel endothelium and allowing entry of T-cells,
monocytes/macrophages, and neutrophils. Cytokine produced by Th1 cells activate
macrophages causing the release of TNF-α promoting further migration from the blood
into the joint. IL-1 is produced in the joint by macrophages and neutrophils leading to
tissue destruction by infiltrating cells and synoviocytes, chondrocytes, and fibroblasts. A
positive feedback continues due to release of joint antigens and inflammatory mediators,
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which persists even as T-cell numbers decrease [Luross et al. 2001]. Dexamethasone given
i.p. at for 5 days at high dose has been shown to be effective in the CIA model. In the same
study by Kang et al. responses were shown to improve with co-administration of IL-4
[Kang et al. 2000]. The mechanism of induction of arthritic paws in the B6C3F1 mouse is
unknown and may differ from that of the H-2q mice. The results shortly following
implantation of DEX-EPCL did have trends that could if tested and repeated with a larger
sample size result in suppression of footpad swelling over MO controls. However, the
cause of all groups having increased footpad swelling, although small in number, during
later timepoints is unknown and is in contrast to H-2q mice that would begin to see waning
footpad swelling in the model overall by that time. Further study of the CIA model in the
B6C3F1 mouse is warranted.

Conclusion
The DEX-EPCL studies indicate that the system has potential for local drug
delivery of immunomodulators while reducing or eliminating systemic effects. The DEXEPCL system was highly successful in the C. albicans delayed-type hypersensitivity
response. The keyhole limpet hemocyanin model again pointed to the 70 DEU dose as a
dose capable of local immunosuppression without systemic effects, however model was
inconsistent. No statistically significant effects were observed in the collagen-induced
arthritis model and further study of the model in the B6C3F1 mouse may provide further
insight.
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CHAPTER 8: Conclusions and Future Work
Results indicate that EPCL is an excellent polymer for immunocompatibility.
EPCL was shown to have no effect on young or aged animals in a microfibrous and a
nanofibrous form. Studies were conducted based on results from in vitro studies by Smith
et al. suggesting that electrospun polymers could potentially cause immunosuppression
[Smith et al. 2007, Smith et al. 2010, Smith et al. 2011]. Several disadvantages exist with
in vitro testing including: direct contact of the material with the cells in culture, the
production and lack of removal of cellular waste products, limited exposure time, and lack
of signals and cells found in vivo. Currently, in vitro immunotoxicity testing can not be
directly correlated with in vivo exposure and these disadvantages may explain the contrast
in results presented compared to the work of Smith et al. [McLoughlin et al. 2012, Smith et
al. 2007, Smith et al. 2010, Smith et al. 2011].
Preliminary drug delivery studies are promising that EPCL may be a good
candidate for a local drug delivery system for immunomodulators. The work could be
continued in many different directions. The studies presented only address the effects of
EPCL after 28 days of implantation where the polymer does not present macroscopic signs
of degradation, studies of long-term implantation and the role of degradation and
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degradation products would present important information on the long-term safety of
EPCL. Chronic inflammation at the implant site may also be a factor in long-term
implantation and may be lessened or alter with the presence of dexamethasone.
Through in vitro testing and in silico modeling the parameters of the drug delivery
system could be optimized. The in vitro release profile could be characterized using a
method similar to Martins et al. DEX-EPCL could be placed in saline and incubated at
37°C and media samples taken at various timepoints. The presence of dexamethasone
could then be measured using UV-VIS at 242 nm and concentration calculated from a
standard curve [Martins et al. 2010]. The in vitro release profile could then be used in drug
delivery modeling and parameters such as DEX concentration and scaffold thickness could
be optimized. Following the in vitro and in silico work the new system could then be tested
in the in vivo models.
Additional types of compounds could be incorporated, such as antibodies or
antibodies directed against cytokines. Similarly, multiple types of treatment could be
incorporated and a combinatorial product optimized. For example, IL-4 in combination
with dexamethasone has been show to increase efficacy in the CIA model [Kang et al.
2000]. Different polymers could also be used, by incorporating a faster degrading polymer
drug release may occur more quickly. The amount of polymer encapsulation should be
characterized to determine if there is a physical barrier to drug delivery. Finally, ideally
the work could continue into creation of a tissue engineering therapy for rheumatoid
arthritis where damaged cartilage could be replaced or regenerated.
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